Express Pharma
Home  »  Latest Updates  »  Commerce Secretary Rita Teaotia inaugurates 4th edition of iPHEX

Commerce Secretary Rita Teaotia inaugurates 4th edition of iPHEX

23

Over 600 overseas business visitors, from over 100 countries, including regulators, senior health officials, media persons, NGO representative to participate at the event

The fourth edition of iPHEX 2016 was inaugurated by Commerce Secretary Rita Teaotia. Speaking at inauguration, the Commerce Secretary said that the objectives of iPHEX converges with idea of creating business opportunities for all, with the novel cause of taking care of health of citizens globally.

iPHEX is the initiative of Ministry of Commerce, Govt of India and organised by Pharmaceuticals Export Promotion Council of India (PHARMEXCIL) with the goal to take the Indian pharma sector to the next level in the international market.

iPHEX-2016 is the fourth edition of the biggest networking event for Indian pharma sector which aims to bring pharma and healthcare sector under one umbrella. Over 600 overseas business visitors, from over 100 countries, including regulators, senior health officials, media persons, key representatives from NGOs are set to participate in the three day event. One of the unique feature of this showcase and interaction platform is focused business meetings in various sessions spread from April 27-29, 2016.

The event will be co-located with PHARMA Pro&Pack Expo 2016, a show for pharma machinery manufacturers. iPHEX 2016 will offer industry majors from India and all across the world a great platform to connect and do business.

According to Ashutosh Gupta, Chairman, Pharmexcil, generic drugs form the largest segment, with 75 per cent of market share (in terms of revenues), of the Indian pharma sector. India supplied 20 per cent of the global generic medicines market exports in terms of volume, making the country the largest provider of generic medicines globally. This share is expected to expand further in the coming years. Over-the-Counter (OTC) medicines and patented drugs constitute 21 per cent and nine per cent, respectively, of total market revenues of $20 billion.

EP News BureauMumbai

Comments are closed.